Benzydamine
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Benzydamine
- Benzydamine: From Local Oromucosal Anti-inflammatory Use to Benign Prostatic Hyperplasia
Benzydamine: From Local Oromucosal Anti-inflammatory Use to Benign Prostatic Hyperplasia
One-Sentence Summary
Benzydamine is a locally acting anti-inflammatory and analgesic agent, marketed in Singapore as throat sprays, lozenges, mouthwashes and a mouth gel. The TxGNN model predicts it may be effective for benign prostatic hyperplasia (top-ranked prediction), but no clinical trials and no publications currently support this specific prediction. Among the other predicted indications, only common cold (sore throat symptoms) and peripheral vascular disease (venous inflammation) have any supporting literature.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the registration records compiled for this report (products are throat sprays, lozenges, mouthwashes and a mouth gel) |
| Predicted New Indication | Benign prostatic hyperplasia |
| TxGNN Prediction Score | 99.26% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 13 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, benzydamine is a locally acting NSAID-like agent with anti-inflammatory, local anaesthetic and membrane-stabilising properties. Its efficacy in oropharyngeal inflammation and pain is established, and mechanistically it may be applicable to conditions involving inflammation.
For benign prostatic hyperplasia, a link to prostatic inflammation is possible but speculative. No data compiled for this report support it. The high TxGNN score (0.993) is a computational prediction only. Benzydamine is also used in Singapore only in oromucosal and topical forms, so reaching prostate tissue would require a different route of administration, which has not been assessed.
Other predictions carry different levels of support:
- Common cold (rank 5, L3): Benzydamine is an established agent for sore throat and pharyngeal inflammation, which are cold symptoms. The evidence relates to symptom relief, not treatment of the viral illness itself.
- Peripheral vascular disease (rank 4, L4): Older studies (1967–1976) describe benefit in superficial venous inflammation and thrombophlebitis. This is indirect for vascular disease as a whole, particularly arterial disease.
- Headache disorder, trigeminal autonomic cephalalgia, peripheral arterial disease, breast carcinoma, toxocariasis, subarachnoid haemorrhage, alopecia: No supporting evidence. These are prediction-only (L5), and several have no plausible mechanism.
Clinical Trial Evidence
Currently no related clinical trials registered for benign prostatic hyperplasia. No registered trials were found for any of the top 10 predicted indications.
Literature Evidence
Currently no related literature available for benign prostatic hyperplasia.
For reference, literature was found for two other predicted indications:
Common cold (rank 5)
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 37000110 | 2023 | Phase IV randomised trial | Medicine | Compared speed of pain relief of benzydamine 0.3% oromucosal spray vs 3 mg lozenges in acute sore throat |
| 31718214 | 2019 | Comparative pilot study | Acta Med Acad | Lysozyme vs benzydamine vs chlorhexidine oral sprays in acute tonsillopharyngitis associated with a common cold |
| 40626097 | 2025 | Methodological paper | Front Pain Res | Development and refinement of the sore throat pain model for measuring acute pain treatment effects |
| 8984600 | 1996 | Double-blind study | Schweiz Med Wochenschr | Rhinomanometric comparison of three nasal sprays, including benzydamine, in 60 common cold patients (indirect relevance) |
Peripheral vascular disease (rank 4)
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 772478 | 1976 | Controlled clinical study | Minerva Med | Double-blind comparison of topical feprazone and benzydamine in thrombophlebitis; both active and well tolerated, feprazone cured faster |
| 5622836 | 1967 | Clinical observation | Minerva Dermatol | Benzydamine in inflammatory phlebopathies of the lower limbs |
| 5123780 | 1971 | Clinical observation | Phlebologie | Benzydamine hydrochloride as an anti-inflammatory agent in angiology |
| 5397591 | 1969 | Clinical observation | Il Policlinico | Benzydamine plus tetracycline in acute and subacute inflammation |
| 5382105 | 1969 | Clinical observation | Clin Ter | Anti-inflammatory activity of benzydamine plus tetracycline |
| 5606258 | 1967 | Clinical observation | Minerva Dermatol | Benzydamine use in dermatology (indirect) |
Singapore Market Information
Approved indication text was not available in the registration records compiled for this report. Thirteen single-ingredient licences are valid; the main ones are listed below.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN13626P | Difflam For Children Throat Spray | Spray | Not stated |
| SIN17050P | Tymora Throat Spray 0.3% w/v | Spray | Not stated |
| SIN07411P | Difflam Lozenge 3 mg | Lozenge | Not stated |
| SIN04232P | Difflam Solution 22.5 mg/15 ml | Mouthwash | Not stated |
| SIN09963P | Difflam Mouth Gel | Gel | Not stated |
Safety Considerations
Please refer to the package insert for safety information. No warnings, contraindications or drug interaction records were available in the data compiled for this report.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction for benign prostatic hyperplasia rests solely on a computational score, with no trials, no literature and no established mechanism. The drug is available in Singapore only in oromucosal and topical forms, which are not obviously suited to this condition. Among the other predictions, common cold (symptomatic sore throat relief, L3) is the best supported, but it largely overlaps with benzydamine's existing use rather than being a true new indication.
To proceed, the following is needed:
- Package insert warnings, contraindications and approved indications from the HSA, to allow safety screening
- Mechanism of action data (for example from DrugBank)
- A literature search on benzydamine and prostatic inflammation or lower urinary tract symptoms
- Assessment of route and formulation compatibility for any prostate-directed use
- If a lower-risk direction is preferred, a review of the common cold and thrombophlebitis evidence to judge whether these are meaningful new indications
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.